1. Pink Sheet

Biden’s Abortion Strategy Omits Regulatory Changes That Could Boost Mifepristone Access

 
• By Brenda Sandburg

HHS report on protecting reproductive care shows administration is reluctant to take bold actions to counter Supreme Court’s Dobbs decision. Report does not suggest revising or eliminating mifepristone’s REMS or seeking preemption legal battles as some advocates have urged.

Abortion restriction
HHS does not propose how to overcome restrictions on abortion medication • Source: Shutterstock

Last month, President Biden directed the Department of Health and Human Services to issue a report identifying potential actions to expand access to medication abortion. While reproductive rights advocates offered HHS suggestions, the department did not adopt them or propose any plan to increase access to mifepristone.

The report, released on 26 August, simply notes the US Food and Drug Administration’s ongoing modification of the mifepristone Risk Evaluation and Mitigation Strategy (REMS) announced in December

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership